Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) FCF Margin (2016 - 2025)

Historic FCF Margin for Sunshine Biopharma (SBFM) over the last 9 years, with Q3 2025 value amounting to 7.81%.

  • Sunshine Biopharma's FCF Margin rose 144000.0% to 7.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.84%, marking a year-over-year increase of 195500.0%. This contributed to the annual value of 40.68% for FY2024, which is 39200.0% down from last year.
  • Sunshine Biopharma's FCF Margin amounted to 7.81% in Q3 2025, which was up 144000.0% from 15.23% recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's FCF Margin registered a high of 7.81% during Q3 2025, and its lowest value of 1192.65% during Q3 2021.
  • Its 5-year average for FCF Margin is 324.89%, with a median of 59.68% in 2024.
  • Within the past 5 years, the most significant YoY rise in Sunshine Biopharma's FCF Margin was 11471300bps (2021), while the steepest drop was -6288900bps (2021).
  • Quarter analysis of 5 years shows Sunshine Biopharma's FCF Margin stood at 366.68% in 2021, then soared by 83bps to 61.95% in 2022, then skyrocketed by 52bps to 30.04% in 2023, then dropped by -22bps to 36.63% in 2024, then soared by 79bps to 7.81% in 2025.
  • Its FCF Margin stands at 7.81% for Q3 2025, versus 15.23% for Q2 2025 and 19.34% for Q1 2025.